In contrast, in two patients with breast cancer and esophageal cancer, who had FISH-confirmed HER2 amplification, disease progression occurred within around 80 days of starting TAS0728 treatment at 50 mg BID and 100 mg BID, respectively. Here, ERBB2 is linked to breast carcinoma.